Alpha-2A Adrenergic Receptor Protein

ADRA2A Protein (Alpha-2A Adrenergic Receptor)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Alpha-2A Adrenergic Receptor Protein</th>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Gi/o protein coupling</td>
<td>Inhibits adenylate cyclase</td>
</tr>
<tr>
<td class="label">Reduced cAMP</td>
<td>Decreases PKA activity</td>
</tr>
<tr>
<td class="label">K+ channel activation</td>
<td>Hyperpolarizes [neurons](/entities/neurons)</td>
</tr>
<tr>
<td class="label">Ca2+ channel inhibition</td>
<td>Reduces transmitter release</td>
</tr>
<tr>
<td class="label">Class</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">Agonists</td>
<td>Clonidine, Guanfacine, Dexmedetomidine</td>
</tr>
<tr>
<td class="label">Antagonists</td>
<td>Yohimbine, Idazoxan, Fipamezole</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/anxiety" style="color:#ef9a9a">Anxiety</a>, <a href="/wiki/dementia" style="color:#ef9a9a">Dementia</a>, <a href="/wiki/depression" style="color:#ef9a9a">Depression</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-4113b0e8" style="color:#ce93d8" title="Score: 0.47">Noradrenergic-Tau Propagation Blockade...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="

...

ADRA2A Protein (Alpha-2A Adrenergic Receptor)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Alpha-2A Adrenergic Receptor Protein</th>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Gi/o protein coupling</td>
<td>Inhibits adenylate cyclase</td>
</tr>
<tr>
<td class="label">Reduced cAMP</td>
<td>Decreases PKA activity</td>
</tr>
<tr>
<td class="label">K+ channel activation</td>
<td>Hyperpolarizes [neurons](/entities/neurons)</td>
</tr>
<tr>
<td class="label">Ca2+ channel inhibition</td>
<td>Reduces transmitter release</td>
</tr>
<tr>
<td class="label">Class</td>
<td>Examples</td>
</tr>
<tr>
<td class="label">Agonists</td>
<td>Clonidine, Guanfacine, Dexmedetomidine</td>
</tr>
<tr>
<td class="label">Antagonists</td>
<td>Yohimbine, Idazoxan, Fipamezole</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/anxiety" style="color:#ef9a9a">Anxiety</a>, <a href="/wiki/dementia" style="color:#ef9a9a">Dementia</a>, <a href="/wiki/depression" style="color:#ef9a9a">Depression</a></td>
</tr>
<tr>
<td class="label">SciDEX Hypotheses</td>
<td><a href="/hypothesis/h-4113b0e8" style="color:#ce93d8" title="Score: 0.47">Noradrenergic-Tau Propagation Blockade...</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">94 edges</a></td>
</tr>
</table>

Introduction

Alpha 2A Adrenergic Receptor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

The ADRA2A protein (alpha-2A adrenergic receptor) is a G protein-coupled receptor that mediates the effects of norepinephrine and epinephrine. It plays critical roles in regulating sympathetic tone, neurotransmission, blood pressure, and analgesia. ADRA2A is an important therapeutic target for hypertension, ADHD, and [Parkinson's disease](/diseases/parkinsons-disease-disease).

Structure

Receptor Architecture

• 7 transmembrane domains: Classic GPCR structure
• N-terminal extracellular domain: Glycosylation sites
• C-terminal intracellular domain: G protein coupling
• Disulfide bonds: Extracellular domain stabilization

Ligand Binding

• Orthosteric site: Binds catecholamines (norepinephrine, epinephrine)
• Allosteric sites: Modulator binding pockets
• Agonist binding: Activates receptor
• Antagonist binding: Blocks receptor activity

Function

Signaling Pathways

Physiological Roles

• Sympathetic Nervous System: Reduces norepinephrine release
• Blood Pressure: Mediates vasoconstriction (central effect)
• Analgesia: Modulates pain pathways
• Glucose Metabolism: Affects insulin secretion
• Platelet Function: Reduces platelet aggregation

Expression

• Central nervous system (locus coeruleus, [cortex](/brain-regions/cortex), spinal cord)
• Peripheral sympathetic nerves
• Platelets
• Pancreatic beta cells

Disease Associations

Parkinson's Disease

• Levodopa-Induced Dyskinesia: ADRA2A overexpression in D1-responsive neurons
• Therapeutic Strategy: ADRA2A antagonists (e.g., idazoxan) reduce LID
• Clinical Trials: Fipamezole (ADRA2A antagonist) for LID

ADHD

• Genetic Variants: Associated with ADHD risk
• Treatment Response: May predict response to stimulants

Other Conditions

• Hypertension: Target of clonidine, guanfacine
• Opioid Withdrawal: Mediates autonomic symptoms
• Glaucoma: Apraclonidine eye drops

Therapeutic Targeting

Drug Classes

Clinical Development

• Fipamezole: Phase II for levodopa-induced dyskinesia in PD
• Novel PAMs: Positive allosteric modulators in development

See Also

• [ADRA2A Gene](/proteins/adra2a-protein)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Locus Coeruleus Neurons](/cell-types/locus-coeruleus-neurons)
• [Dopaminergic Treatment](/therapeutics/dopamine-replacement-therapy)

External Links

• [UniProt: P08913](https://www.uniprot.org/uniprot/P08913)
• [PDB: 5K7A](https://www.rcsb.org/structure/5K7A)
• [IUPHAR/BPS Guide: ADRA2A](https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=18)

Research Directions

Recent research has focused on understanding ADRA2A's role in neurodegenerative disorders beyond its traditional indications. Studies are investigating:

• [Neuroprotection*: ADRA2A activation may provide neuroprotective effects through reduced excitotoxicity](/genes/ide)
• [Neuroinflammation*: Modulation of microglial activation states via adrenergic signaling](/mechanisms/neuroinflammation)
• [Cognitive Function*: Role of ADRA2A in prefrontal cortical function and working memory](/institutions/emory)
• [Sleep-Wake Regulation*: Central ADRA2A signa](/genes/adra2a)ling promotes sedation and sleep

Biomarker Potential

• ADRA2A expression levels in peripheral blood mononuclear cells as a biomarker
• Genetic variants predicting treatment response

Future Therapeutic Applications

• Combination Therapies: ADRA2A modulators with dopaminergic agents
• Targeted Delivery: Nanoparticle-based CNS delivery of ADRA2A-targeting compounds
• Personalized Medicine: Genetic stratification for ADRA2A-targeted treatments

Animal Models

• ADRA2A Knockout Mice: Show increased sympathetic tone, hypertension
• Transgenic Models: Overexpression models for LID studies
• Non-human Primates: Primate models for therapeutic development

Key Publications

ADRA2A antagonists for levodopa-induced dyskinesia: Studies showing reduction in dyskinesia severity with fipamezole treatment

ADRA2A genetic variants and ADHD: Association studies linking polymorphisms with ADHD risk and treatment response

ADRA2A and neuroprotection: Evidence for anti-apoptotic effects in cellular models

Background

The study of Alpha 2A Adrenergic Receptor Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[<sup>Aragues M, et al, (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31785023/)

[<sup>Sanchez-Soto M, et al, (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29472353/)

[<sup>Roh J, et al, (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34160294/)

[<sup>Filip M, et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32380348/)

[<sup>Lee A, et al, (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31019317/)